Skip to content

Cytokinetics CYTK Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Merck & Co. logo
Merck & Co.MRK
$157M+726%
Medtronic logo
MedtronicMDT
$97M-10.2%

Other financials

Income statement

See full
Revenue$19.4M+1,126%
Operating income-$183.6M-18.0%
Net income-$206.0M-27.7%
EPS (diluted)-$1.67-22.8%

Balance sheet

See full
Cash & equivalents$129.8M+76.2%
Total debt$418.2M+75.8%
Total equity-$826.6M-210%
Total assets$1.3B+0.7%

Cash flow

See full
Operating cash flow-$145.5M-10.5%
CapEx$5.9M+4.7%
Free cash flow-$151.4M-10.3%

Valuation

See full
Market cap$10.7B+70.6%
Enterprise value$10.98B+70.7%
P/S101.1×-225×

Profitability

See full
Operating margin-605.1%-268pp
Net margin-784%-337pp
FCF margin-518.8%-223pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytokinetics's stock issuance proceeds?
Cytokinetics (CYTK) reported stock issuance proceeds of $11.35M in Q1 2026.
What does stock issuance proceeds mean?
Cash received from selling company shares to investors or employees.
How do you interpret stock issuance proceeds?
An increase indicates successful capital raising or high employee participation in equity plans, while a decrease may suggest reduced reliance on equity financing.
How does stock issuance proceeds compare across companies?
Standard across all public companies; biotech firms often show higher volatility due to frequent secondary offerings.